The Research of Treg Cells : Progress and Challenge

T regulatory cells (Tregs) play an important role in the induction and maintenance of immunological tolerance to self and alloantigens. Recent findings in experimental transplant models have demonstrated that Treg could control and delay allograft rejection. Induction of immune tolerance decreases the risk of acute and chronic graft rejection after solid organ transplantation and can improve transplanted organ survival. Tregs are being tested in trials as a potential therapy in cell and solid organ transplantation. However, as we know, regulatory T cells (Tregs) are crucial for peripheral tolerance and are intimately involved in cancer. The influence of Tregs on cancer progression has been demonstrated in a large number of preclinical models and confirmed in several types of malignancies. Neoplastic processes trigger an increase of Treg numbers in draining lymph nodes, spleen, blood, and tumors, leading to the suppression of anti-tumor responses. In this review, we summarize some of the critical aspects of the immunoregulatory function of Treg cells in cancer and transplantation and discuss their potential research progress and challenge.


Introduction
Recently, characteristic and function of Treg cells research achieved significant progress.Especially, its role in immune tolerance has been confirmed by more and more experiment [1]- [5].However, because of its immunosuppression, the influence of Treg cells on cancer progression has been demonstrated in a large number of preclinical models and confirmed in several types of malignancies [6]- [11].How to deal with the Treg cells in the balance between transplantation tolerance and cancer?Here, we discuss the progress of Treg cells and comment on their challenge between immune tolerance and cancer.

Characteristic and Function of Tregs
Regulatory T cells are suppressive T cells that have an essential role in maintaining the balance between immune activation and tolerance.The induction and maintenance of immune tolerance to transplanted tissues constitute an active process involving multiple mechanisms that work cooperatively to prevent graft rejection.These mechanisms are similar to inherent tolerance toward self antigens and have a requirement for active immunoregulation, largely T cell mediated, that promotes specific unresponsiveness to donor alloantigens.The major target for Treg cells is T cells, Nonetheless, recent studies have also demonstrated that Treg cells also exert their effects on B cells and other cells including mast and Veto [40]- [46].Suppressive mechanisms of Tregs for T cells can be divided into three categories: cell-cell contact, local secretion of inhibitory cytokines and local competition for growth factors (Figure 3 from Dorothy K Sojka et al.) [47].In each category there are multiple examples of inhibitory pathways that are probably not mutually exclusive.Treg cells can suppress B cell responses and control B cell-mediated diseases (Figure 4 from Lim HW et al.) [48].evidence is provided through studying the patients with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) patients who lack Treg cells.Multiple and diverse autoantibodies are commonly identified in the sera of IPEX patients, suggesting that Tregs represent a key regulator for autoreactive B cells [49]- [53].FOXP3 deficiency resulted in the accumulation of autoreactive clones in the mature naive B-cell compartment of IPEX patients, providing direct evidence for the role of Tregs in maintaining B-cell tolerance [54]- [57].At the same time, treg cells can suppress the activation, proliferation, differentiation and effector function of various immune cells, including CD4 + and CD8 + T cells, dendritic cells (DC) and natural killer cells [58] [59] via different mechanisms, depending on the target and location of their action.The allograft (e.g., heart) will be transplanted with concomitant infusion of donor BM or HSC into conditioned hosts.Rejection of the grafts will temporarily be prevented using an immunosuppressive regimen.( 2) Donor (a) and host (b) BM will be cultured in vitro under conditions allowing for differentiation of DC.Host DC will be pulsed with donor antigen to assure indirect presentation of these antigens.Thus generated DC will then be co-cultured with host-derived Treg (c), allowing for expansion of Treg specific for directly and indirectly presented donor antigens.

Tregs and Transplantation Immune Tolerance
(3) Thus generated donor-antigen-specific Treg will then be infused into the host.Immunosuppression may temporarily be continued using drugs that do not affect Treg (e.g., Rapamycin).Using this protocol, full tolerance to donor-tissue will be achieved and chronic rejection effectively prevented.

Tregs and Cancer
There has been an explosion of literature focusing on the role of regulatory T (Treg) cells in cancer immunity.It is becoming increasingly clear that Treg cells play an active and significant role in the progression of cancer, and have an important role in suppressing tumor-specific immunity (Figure 9 from Guillaume Darrasse-Jèze et al.) [74].At the same time, Researchers have identified Treg cell may also play an important role in immune evasion mechanisms employed by cancer [75]- [84] (Figure 10 from Guillaume Darrasse-Jèze et al.) [74].Tumor-associated Tregs are thought to follow one of two developmental pathways in order to enter the Foxp3 + Treg lineage.First, a developing thymocyte may recognize self antigen presented within the thymus during T cell maturation (Pathway 1, referred to as natural Tregs ("nTregs").Alternatively, a conventional CD4 + T cell may encounter a tumor-associated (self) or tumor-specific ("neo") antigen in the tumor environment, become activated, and under the influence of an immunosuppressive tumor microenvironment, differentiate into a Foxp3 + Treg (Pathway 2, referred to as induced Tregs ("iTregs").Next, within the tumor environment, Tregs may respond to context-dependent inflammatory signals (e.g.Th1, Th2, or Th17 inflammation), the tissue or organ type (e.g.colon, breast, or prostate) and even the immediate proximal microenvironment (e.g.stroma, tumor bed, or lymphoid cluster).From these environmental cues, Tregs are capable of mediating distinct functions, which may include promotion of angiogenesis or metastasis, regulation of inflammation, and suppression of anti-tumor adaptive immune responses (Figure 11 from Peter A. Savage et al.) [85].Tumors may differentiate, expand, recruit, and activate Treg (tumor Treg) cells via multiple mechanisms and potently abrogate antitumor   immunity [86]- [93].Figure 12 shows a schematic diagram of tumor-mediated generation of Treg cells in tumor microenvironment.Guillaume Darrasse-Jèze and Katrina Podsypanina reported activated memory Tregs in the Early Immune Response to Cancer (Figure 13 from Guillaume Darrasse-Jèze et al.) [75].and immune tolerance vs. immune rejection decision process (Figure 14 from Guillaume Darrasse-Jèze et al.) [75].

Prospect of Treg Cells Research
Treg cells play an indispensable role in the immune system as they are involved in the prevention of autoimmune diseases, allergies, infection-induced organ pathology, transplant rejection as well as graft versus host disease (GvHD) by suppression of effector T cells and other immune cells.As we know from above Treg cells can induce immune tolerance to decrease the risk of acute and chronic graft rejection after solid organ transplantation and improve transplanted organ survival [94]- [96].On the other hand, they are also contributed to the progress of many tumours.As cancer cells express both self-and tumour-associated antigens, Treg cells are the key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti-tumour responses.How to deal with the Treg cells in the balance between transplantation tolerance and cancer (Figure 15      function and Teff/Treg ratios; 9) use the target of specific Treg subsets to prevent tumor [102] [103].In a word, the research of Treg cells is an interesting subject and worth to intensively investigate.

Figure 1 .
Figure 1.Origin and classification of Treg cells.Treg cells production in the thymus and periphery.Natural (n) Treg cells are generated by high-avidity selection in the thymus.Inducible (i) Treg cells derive from antigenstimulated naïve T cells in the periphery.nTreg cells can promote iTreg cells development by cytokine-dependent mechanisms.

Figure 2 .
Figure 2. Natural and adaptive regulatory T cells.Natural regulatory T cells produced by the thymus and adaptive regulatory T cells that are induced in the periphery upon antigenic stimulation of naive T cells under tolerogenic conditions.

Figure 3 .
Figure 3. Mechanisms of regulatory T-cell (Treg) suppression.(a) Cell-cell contact.Tregs may suppress target cells via direct interaction of receptor-ligand pairs on Tregs and target cells; delivery of suppressive factors via gap junctions including cyclic adenosine monophosphate (cAMP); direct cytolysis; membrane-bound suppressive cytokines such as transforming growth factor-β (TGF-β); and/or indirectly via modulating the antigen-presenting cell (APC) through cell-cell contact, possibly through reverse signalling via Treg-cytotoxic T-lymphocyte antigen-4 (CTLA-4) engagement of B7 on dendritic cells; (b) Soluble suppressive factors.Tregs can directly secrete interleukin-10 (IL-10), TGF-β and IL-35 or induce APCs to secrete such factors.Expression of CD73/CD39 by Tregs facilitates the local generation of adenosine that can down-modulate immune function; (c) Competition.Tregs may compete for some cytokines that signal via receptors that contain the com mon γ-chain (IL-2, IL-4 and IL-7).Additionally they may compete for APC costimulation via constitutive expression of CTLA-4.Red arrow indicates an inhibitory signal.

Figure 4 .
Figure 4. Schematic diagram for the roles of Treg subsets on B cell.Both nTreg and iTreg cells suppress Th cell response that is important for B cell activation.However, both Treg cells also directly suppress B cell response through different mechanisms.While nTreg cells kill B cell through the secretion of Perforin and Granzyme B, iTreg cells suppress B cell response through immune suppressive cytokines including TGF-β and IL-10.Both Treg cells may have synergetic role on B cells to regulate the production of antibodies.It is unclear so far whether both Treg cells directly suppress plasma cells.

Figure 5 .
Figure 5.A regulatory T cell/hematopoietic chimerism-based protocol for induction of transplantation tolerance.(1)The allograft (e.g., heart) will be transplanted with concomitant infusion of donor BM or HSC into conditioned hosts.Rejection of the grafts will temporarily be prevented using an immunosuppressive regimen.(2) Donor (a) and host (b) BM will be cultured in vitro under conditions allowing for differentiation of DC.Host DC will be pulsed with donor antigen to assure indirect presentation of these antigens.Thus generated DC will then be co-cultured with host-derived Treg (c), allowing for expansion of Treg specific for directly and indirectly presented donor antigens.(3)Thus generated donor-antigen-specific Treg will then be infused into the host.Immunosuppression may temporarily be continued using drugs that do not affect Treg (e.g., Rapamycin).Using this protocol, full tolerance to donor-tissue will be achieved and chronic rejection effectively prevented.

Figure 6 .
Figure 6.Tolerance mechanisms induced by the proposed regulatory T cell/hematopoietic chimerism-based protocol for induction of transplantation tolerance.(1) Hematopoietic cells (e.g., DC) derived from the grafted BM will colonize the recipient's thymus and induce deletion and anergy (i.e., "recessive tolerance") of developing donorspecific host T lymphocytes.DC may also promote limited differentiation of donor-specific Treg that will contribute to transplantation tolerance.(2) Donor DC will also induce recessive tolerance of mature peripheral donor-specific T lymphocytes.These cells may, to a limited extent, directly induce donor-specific Treg.However, the dominant tolerance (i.e., Treg) induce by hematopoietic chimerism in (1) and (2) appears insufficient to durably prevent most notably chronic allograft rejection.(3) Infusion of donor-specific Treg will aid in engraftment of grafted donor BM/ HSC (a) and inhibit the reactivity of mature peripheral donor-specific T lymphocytes (b), thus favoring graft-acceptance.They will also allow the differentiation of donor-specific conventional T lymphocytes into Treg (c), thus assuring persistence of tolerance and preventing chronic allograft rejection.

Figure 9 .
Figure 9. Mechanisms of Treg cells inhibition for cancer.(a) Secretion of immunosuppressive cytokines (IL-10, IL-35 and TGFβ) inhibiting effector T cells; (b) Cytolysis of effector T cells by production of Granzyme A and/or B; (c) Metabolic disruption of effector T cells by IL-2 deprivation.IL-2 is captured by CD25 expressed by Treg; (d) Inhibition of DC maturation by contact-dependent mechanisms (CTLA-4, CD80-CD86 interaction, Lag3/ CMHII interaction) and effector function by IDO secretion.

Figure 10 .
Figure 10.Recruitment, proliferation and induction of Treg in the tumor microenvironment.(i) Recruitment of CCR4 + activated Treg by a CCL22 gradient produced by the tumor.(ii) Tumor expression of VEGF, IL-10 or TGFβ blocks DC maturation responsible for Treg induction and proliferation.(iii) TGFβ secreted by the tumor converts conventional CD4 + T cells into regulatory T cells.

Figure 11 .
Figure 11.Conceptual model describing the biology of tumor-associated Tregs.Pathway 1: a developing thymocyte may recognize self antigen presented within the thymus during T cell maturation.Pathway 2: a conventional CD4 + T cell may encounter a tumor-associated (self) or tumor-specific ("neo") antigen in the tumor environment, become activated, and under the influence of an immunosuppressive tumor microenvironment, differentiate into a Foxp3 + Treg.
from Eefje M et al.)[97]?The successful application of Treg therapy in allograft and at the same time prevent tumor formation, there are multiple issues addressed: 1) the efficacy of Treg and the number of cells necessary to obtain a therapeutic effect[85] [98]; 2) the Ag specificity necessary for safe and effective control of rejection; 3) the stability of the suppressive phenotype of adoptively-transferred Treg[82] [99] [100]; 4) the Treg migratory pattern that guarantees the strongest regulatory function; 5) the conditions permissive to regulation of the memory response; 6) the ability of Treg to control the xeno-reactive response; 7) the impact of lymphocyte depletion/concomitant immunosuppressive therapy on Treg function.So Treg cells are subject to intense investigations[88] [101]; 8) strategies to target cancer will rely on combining control of Treg cells

Figure 12 .
Figure 12.Tumor-mediated generation of regulatory T (Treg) cells and the effect on the tumor microenvironment.Tumor cells induce the generation of Treg cells through both cell contact-dependent and cell contact-independent mechanisms.Soluble protein such as TGFβ produced by tumor cells promote the proliferation of Treg cells and induce the conversion of naive CD4 + CD25 − T cells into Treg cells.Tumor cells also express costimulatory molecules such as CD80/CD86 or CD70 and interact with naive T cells to convert these naive T cells into Treg cells.The increased numbers of Treg cells inhibit the NK cells, CD4 + T cells, CD8 + T cells and the other cells and contribute to the progression of tumors.

Fiigre 13 .
Early events during cancer emergence lead to immune tolerance against tumor.Activated memory Tregs (AmTregs or amTr, beige lymphocytes) are the first to be stimulated by the presence of the tumor (gray round-shaped cells) via recognition of self-Ag presented by dendritic cells (DCs, star-shaped cells) coming from the tumor site (t1).AmTreg will then proliferate faster than TAA-specific Teffs (Th, gray lymphocytes) that are naïve (or have already been suppressed at the steady state).AmTreg will then inhibit either Teff activation, proliferation, migration, and function either/or DCs presentation and costimulation (t2).

Figure 14 .
Figure 14.Immune tolerance vs.Immune rejection decision process.Activation kinetics and memory status of Tregs (green) and Teffs (red) in the tumor-draining lymph nodes (dLNs, left) after stimulation by dendritic cells (DC, blue) result in the infiltration of the tumor by different cell subsets with different speed and different tumor fate (right, with tumor cells in gray).

Figure 15 .
Figure 15.Reduction or increase in Treg cell numbers/activity is implicated in various pathologies.Reduction in Treg cell numbers or activity results in the development of autoimmunity, allergy and graft rejection.Increases in Treg cell numbers or aberrant function may cause susceptibility to chronic infection and predispose to tumor development.